SELLAS Life Sciences (SLS) Income from Continuing Operations (2010 - 2026)
SELLAS Life Sciences (SLS) posted quarterly Income from Continuing Operations of 15053000.0 for Q1 2026, down 140.35% year-over-year from 37307850.81 in Q1 2025, and down 80.17% quarter-over-quarter from 8355000.0 in Q4 2025.
Powered by 
Analysis
SELLAS Life Sciences (SLS) Income from Continuing Operations (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Income from Continuing Operations for 15 consecutive years, with 15053000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 140.35% year-over-year to 15053000.0; the TTM figure through Mar 2026 stood at 39620000.0 (down 39.35% YoY), while the FY2025 annual figure was 51112000.0, up 2.42% from the prior year.
- Income from Continuing Operations fell to 15053000.0 in Q1 2026 per SLS's latest filing, from 8355000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 6263000.0 in Q1 2025 and bottomed at 16835000.0 in Q1 2022.
- Historically, Income from Continuing Operations has averaged 9324411.76 across 5 years, with a median of 8723000.0 in 2022.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations tumbled 617.91% — and 2025, when it soared 35.73%.
- SELLAS Life Sciences' Income from Continuing Operations stood at 9646000.0 in 2022, then advanced by 14.19% to 8277000.0 in 2023, then increased by 15.21% to 7018000.0 in 2024, then declined by 19.05% to 8355000.0 in 2025, then tumbled by 80.17% to 15053000.0 in 2026.
- Business Quant data shows SLS's Income from Continuing Operations at 15053000.0 in Q1 2026, 8355000.0 in Q4 2025, and 7283000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -13.27 Mn |
| 10 | SELLAS Life Sciences | 2.62 Bn | 2.62 Bn | - | -9.61 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -9.61 Mn |
| Mar 31, 2026 | -8.41 Mn |
| Dec 31, 2025 | -7.66 Mn |
| Sep 30, 2025 | -6.79 Mn |
| Jun 30, 2025 | -6.60 Mn |
| Mar 31, 2025 | -5.81 Mn |
| Dec 31, 2024 | -6.74 Mn |
| Sep 30, 2024 | -7.11 Mn |
| Jun 30, 2024 | -7.47 Mn |
| Mar 31, 2024 | -9.57 Mn |
| Dec 31, 2023 | -8.14 Mn |
| Sep 30, 2023 | -9.27 Mn |
| Jun 30, 2023 | -8.84 Mn |
| Mar 31, 2023 | -11.28 Mn |
| Dec 31, 2022 | -9.45 Mn |
| Sep 30, 2022 | -7.15 Mn |
| Jun 30, 2022 | -8.62 Mn |
| Mar 31, 2022 | -16.74 Mn |
| Dec 31, 2021 | -11.62 Mn |
| Sep 30, 2021 | -6.98 Mn |